Please use this identifier to cite or link to this item:
http://hdl.handle.net/10668/10783
Full metadata record
DC Field | Value | Language |
---|---|---|
dc.contributor.author | Martín-Gutiérrez, Guillermo | |
dc.contributor.author | Rodríguez-Martínez, José Manuel | |
dc.contributor.author | Pascual, Álvaro | |
dc.contributor.author | Rodríguez-Beltrán, Jerónimo | |
dc.contributor.author | Blázquez, Jesús | |
dc.date.accessioned | 2023-01-25T09:43:02Z | - |
dc.date.available | 2023-01-25T09:43:02Z | - |
dc.date.issued | 2017-03-24 | |
dc.identifier.uri | http://hdl.handle.net/10668/10783 | - |
dc.description.abstract | Escherichia coli variants expressing plasmid-mediated qnr genes are usually susceptible to fluoroquinolones by standard susceptibility testing. Here we show that, under specific urinary tract physiological conditions, susceptible laboratory and clinical strains harboring qnr determinants become fully resistant to ciprofloxacin (CIP). Therefore, physiological conditions, mainly urine pH values, should be considered when performing susceptibility testing of CIP activity against E. coli in treating urinary tract infection (UTI) and for selecting appropriate antibiotics for UTI treatment. | |
dc.language.iso | en | |
dc.subject | Escherichia coli | |
dc.subject | MIC | |
dc.subject | ciprofloxacin | |
dc.subject | pH | |
dc.subject | qnr | |
dc.subject | urinary tract infection | |
dc.subject.mesh | Anti-Bacterial Agents | |
dc.subject.mesh | Ciprofloxacin | |
dc.subject.mesh | Drug Resistance, Bacterial | |
dc.subject.mesh | Escherichia coli | |
dc.subject.mesh | Fluoroquinolones | |
dc.subject.mesh | Humans | |
dc.subject.mesh | Microbial Sensitivity Tests | |
dc.subject.mesh | Plasmids | |
dc.subject.mesh | Urinary Tract Infections | |
dc.title | Plasmidic qnr Genes Confer Clinical Resistance to Ciprofloxacin under Urinary Tract Physiological Conditions. | |
dc.type | research article | |
dc.identifier.pmid | 28096153 | |
dc.rights.accessRights | open access | |
dc.identifier.doi | 10.1128/AAC.02615-16 | |
dc.identifier.essn | 1098-6596 | |
dc.identifier.pmc | PMC5365700 | |
dc.identifier.unpaywallURL | https://europepmc.org/articles/pmc5365700?pdf=render | |
dc.issue.number | 4 | |
dc.journal.title | Antimicrobial agents and chemotherapy | |
dc.journal.titleabbreviation | Antimicrob Agents Chemother | |
dc.organization | IBIS | |
dc.pubmedtype | Journal Article | |
dc.volume.number | 61 | |
dc.type.hasVersion | VoR | |
dc.identifier.pubmedURL | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5365700/pdf | |
Appears in Collections: | Producción 2020 |
Files in This Item:
There are no files associated with this item.
This item is protected by original copyright |
Except where otherwise noted, Items on the Andalusian Health Repository site are licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives License.